Obesity is epidemic in the United States and worldwide. 1, 2 Results from the 1999 National Health and Nutrition Survey estimate that 61% of US adults are either overweight or obese. 3 Strong evidence links obesity to morbidity and mortality, especially for those with underlying cardiovascular diseases. 4 Excessive adipose tissue mass is also associated with sudden cardiac death (SCD). 5, 6 Among the options that protect against SCD, the wearable cardioverter defibrillator (WCD) has been proven to prevent sudden death by immediate cardioversion or defibrillation of life-threatening ventricular tachyarrhythmic episodes. [7] [8] [9] [10] However, there have been concerns regarding the use of WCD in obese patients, even overweight patients, given that their larger chest diameter and body weight might impede defibrillation success. Experimental data suggest that successful defibrillation requires a minimum potential gradient throughout the ventricles. 11 Previous studies on both animals and patients have shown that defibrillation shock success is directly related to body weight; in particular, there is an inverse correlation between body weight and the percentage of patients successfully defibrillated by a given shock strength. 12, 13 Thus, the energy dose/kg approach has been used as a practical method to normalize shock strengths for different body sizes among and across species. Using this methodology, 100 joules is a reasonable estimate of the defibrillation threshold for biphasic waveforms in adult humans, nominally 70 kg. 14, 15 The default delivered energy in modern biphasic external defibrillators is usually 150 joules (2.2 joules/kg) or higher (manufacturer dependent) for shocks 16 to provide an adequate margin of efficacy.
Two of the factors that mitigate a transthoracic shock efficacy are transthoracic impedance (TTI) and electric shunting. 15 TTI refers to the resistance of both cardiac and non-cardiac tissue that affects the current traversing the heart while electric shunting indicates the loss of energy which bypasses the heart through non-cardiac tissues. 17 Although previous studies reported that higher TTI is associated with bigger chest size and fatty tissue, few studies have examined the correlation between obesity and the external shock efficacy.
18-21 Given the increasing demand for SCD protection, as well as the growing obese population, we conducted this retrospective study to evaluate the impact of different obesity levels on WCD shock efficacy and ECG quality. We also assessed patients' WCD wear time and noise level of the ECG signal.
Device description
The wearable cardioverter-defibrillator automatically detects and treats sustained ventricular tachycardia (VT) and ventricular fibrillation (VF). It can deliver up to 5 defibrillations within a single arrhythmia detection cycle, with a programmable energy level from 75 to 150 joules. The device contains a monitor (about 0.77 kg) worn on a hip holster and an electrode belt; the latter holds 4 dry electrodes creating 2 surface electrocardiogram (ECG) channels, positioned in side-to-side (SS) and front-to-back (FB) configurations. The chest garment contains two defibrillation pads on the back; the other counterpart defibrillation pad is attached on the electrode belt at the left anterior part of the chest, close to apical region of the heart. A pair of response buttons on the monitor allow a conscious patient to prevent a potential shock. The WCD also comes with a garment in a variety of sizes in which one inserts the electrode belt. The patients are instructed to wear the device as much as possible during 24 hours, except when taking a shower or bath. At the time of fitting a patient with the WCD, a patient service representative carefully measures the patient's chest in order to find the appropriate garment size in a pre-defined chart according to the measurement. A description of the WCD technical details have been described in the literature. 22 
Methods
All patients prescribed a WCD after-market release in the U.S. are entered into a registry maintained by the manufacturer (ZOLL, Pittsburgh, PA, USA) for regulatory, reimbursement, and administrative purposes. We searched this database for patients who received appropriate shocks by the WCD at least once for ventricular tachyarrhythmias (i.e. sustained VT or VF) between January 1, 2008 and June 1, 2013. All patients signed consent to release their data for quality monitoring and research. All data used for this study were de-identified.
The obesity level was measured and classified by the body mass index (BMI). BMI was extracted directly from available medical records sent by the prescribing hospital center to the manufacturer on a general form used for ordering the WCD. BMI was calculated using the standard formula of weight (in kilograms) divided by the square of the height (in meters). Only patients with known BMI information were included in the analyses. Subjects were then classified as normal (18.0 b BMIb 25.0), overweight (25.0 ≤ BMIb 30.0) or obese (≥30.0BMI). A BMI of 40.0 or greater was used to identify a subgroup of morbidly obese individuals. Demographics (age and gender), indication for WCD prescription and comorbidities were reviewed. Patient wear time (defined as total length of use in days and average daily use in hours), arrhythmia alarms, and WCD treatment information (including the TTI calculated during shock delivery) were stored by the WCD monitor and downloaded for analyses. The ECG quality was measured by the aggregate noise period (seconds) from either SS or FB channel. The rate of noise level was calculated by dividing the total duration of noise period by the total wear time. The occurrence of inappropriate shock from noise was also recorded for this study cohort.
In this study, all appropriate shocks that occurred within a single 24-hour period of the index arrhythmia were coded as one shock event. A post-shock rhythm that was no longer sustained VT or VF, including asystole, was considered a successful arrhythmia termination. The time interval from arrhythmia onset to first defibrillation was recorded, including any time delay from the use of WCD response buttons. Only the first-shock arrhythmia conversion and TTI were included in the analyses. Survival outcome was recorded at 24-hour point after the index event. Long-term survival status was assessed through patient phone calls or a search through the Social Security Death Index. Based on first-shock conversion outcome of the index event, the study cohort was divided into two subgroups: "responder" and "non-responder". Univariate analysis was performed to assess factors which might have contributed to the different shock outcome.
Statistical analysis
All continuous variables were reported as mean ± standard deviation (SD), or medians for skewed distributions; categorical variables were presented as frequencies and proportions. ANOVA was tested for means and Chi-square or Fisher's exact test for proportions. Mann-Whitney test or Kruskal-Wallis test was used for testing the medians for non-normal distribution variables. Pearson's r correlation was used to measure the degree of the relationship between linear related variables. The cumulative survival of patients after the index VT/VF events was analyzed through Kaplan-Meier method. Patients were censored if mortality status was unknown at the time of analyses. Data were considered statistically significant if a 2-sided p value b.05. All statistical analyses were conducted using SPSS version 23 (IBM Corp., Armonk, NY, USA).
Data verification
All ECG review and data analysis were independently verified and approved by physician from University of Rochester.
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Results
During a time period of 66 months (between January 1, 2008 and June 1, 2013), 1135 patients experienced at least one episode of sustained VT/VF and were appropriately treated by the WCD. Of those, 574 had a known BMI and the rest were excluded due to missing a height value. The subgroup with a BMI were representative of the entire cohort as there were no difference between those with and without a BMI. Then BMI values were classified to one of the three pre-specified groups: normal (n = 157, age = 63 ± 16, female = 31.8%), overweight (n = 186, age = 64 ± 12, female = 25.3%) and obese (n = 231, age = 60 ± 11, female = 23.8%). Fifty-five patients were further characterized as morbidly obese for a BMI being equal to or greater than 40. Demographics, WCD indications and clinical information across all groups are summarized in Table I . The differences in programmed VT detection threshold among the three groups were not statistically significant (156 ± 14, 153 ± 17 and 156 ± 13 BPM, respectively, P = .17).
The study cohort experienced 623 shock events. First-shock energy level was 150 joules for 87% of the cases. Appropriate first-shock conversion rate was 92.9% in the normal group, 93.6% and 93.9% in the overweight and obese groups, respectively (P = .93). Of the instances (n = 40) where the first attempt failed to convert VT or VF, 31 were converted by subsequent defibrillations. In three patients, VF followed an initial asystole event (2 in the overweight group and 1 in the obese group). None of these VF events could be terminated by defibrillation therapy and only one patient survived for at least 24 hours post-event. The morbidly obese subgroup had a slightly higher first-shock conversion rate of 96.7%; however, when compared to the rest of the patients in the obese group, the difference was not statistically significant (P = .77). Mean (median) time to shock was comparable across groups, 69 ± 85 (47), 81 ± 170 (47), and 86 ± 181 (48) seconds, respectively (P = .60). On average, the response buttons were used in 14.6% of the arrhythmic events. The distribution of TTI in the various BMI ranges is shown in Figure. The median TTI was 44 ohms, 51 ohms and 65 ohms for the normal, overweight and obese groups, respectively; TTI was positively correlated to BMI (r = 0.33, P b .01). The maximal TTI was 97 ohms for the normal group, 301 for overweight and 581 for obese. Both the 97 ohms and 301 ohms events resulted in first-shock success while the 581 ohms event was converted on a second attempt. Zero impedance was recorded in 4 events (1 in the normal group, 1 in the overweight and 2 in the obese) indicating no contact of the therapy electrode to the skin. Although only 1 had the arrhythmia converted, patients in 2 of the 4 events did survive at least 24 hours. Overall, the 24-hour survival was similar among the three subgroups (91.9%, 94.1% and 92.3%, respectively, P = .66). Use of the response buttons was not associated with difference in either shock efficacy or 24-hour survival. All shocked VT/VF event information is presented in Table II . When dividing the study patients by first-shock success, 531 patients were in the "responder" group and 39 in the "non-responder" group; 4 had unknown first-shock success status due to data corruption. Mean BMI was 29.8 ± 7.8 for the responder group and 28.5 ± 6.6 for the non-responder group (P = .47). Median first-shock impedance was 54 ohms for the responder and 47 ohms for the non-responder (P = .11). The responder group had better 24-hour survival (93% vs. 79.5%, P = .01) as well as cumulative 1-year survival (72.5% vs. 58.0%, P b .01). All other clinical characteristics and wear time parameters were similar between the two groups (Table III) .
Wear time was comparable across groups. The normal BMI group wore the device for 79 ± 131 days on average, while the overweight had 82 ± 202 days and the obese had 55 ± 97 days (P = .12) of wear. The median daily wear time was 21 hours for the normal, 21 for the overweight and 21 for the obese (P = .47). The mean incidence of noise from at least one lead out of total wear time was 2.9 ± 4.1% for the normal group, 2.9 ± 2.7% for the overweight and 4.7 ± 4.6% for the obese (r = 0.27, P b .01). The occurrence of inappropriate shocks triggered by the noise was low and comparable across the three groups which was 0%, 1.6% and 1.3% out of total number of patients in normal, overweight and obese subgroups, respectively (P = .30). Upon WCD discontinuation, the majority of the patients received an ICD (60.6%, 69.6% and 75.2% for normal, overweight and obese subgroups, respectively, P = .24). Death ranked the second reason for WCD discontinuation; the obese group (BMI ≥30) had slightly fewer deaths (13.5%) as an end of use reason than either the normal (24.5%) or the overweight group (18.5%, P = .04 for comparison among the three). Only 4.5% of the study patients were lost to follow-up and the percentages were similar across three groups (P = .37).
Discussion
To our knowledge, this is the first study that evaluates the impact of BMI on WCD shock efficacy to address the concerns over the use of WCD on obese patients. The study results reveal no correlation between BMI and the first-shock success, although the TTI was positively correlated to BMI. No significant differences in wear time were observed among the three BMI groups. The 24-hour event survival was similar across all groups.
TTI is one determinant of transcardiac current flow during defibrillation, which in turn affects shock outcome. For a given device energy delivery setting (e.g. 150 joules), a high TTI reduces transthoracic current flow, which may result in insufficient energy delivered to a critical mass of myocardium. 17, 23 Another shock success determinant is electrical shunting. 17 This means loss of transcardiac current due to an increased proportion traveling through other tissues or mediums, and may result from defibrillation pad displacement, gel smearing, excessive inter-or extra-thoracic tissue or torso structural abnormalities. The last may inversely impact the TTI, as previous studies have shown that larger chest size and abundant fatty tissue correlates with greater TTI. 18, 19 Hence, obese patients are prone to higher TTI and greater chance of transthoracic current loss. The average normal adult TTI is between 70 and 80 ohms. 24 Consistently, the initial EP lab testing reported a measured TTI value for WCD patients to be 64 to 71 ohms. 25 Our study found a higher TTI associated with increased BMI, especially in the morbidly obese group whose average TTI values exceeded both of the above mentioned studies. Although the event with the highest recorded impedance (581 ohms) did not achieve first-shock success, we did not observe any statistical difference in either first-shock conversion or event survival across the groups. Such findings indicate that for the vast majority of cases device delivered shock energy of 150 joules is sufficient to achieve VT or VF conversion with the first shock attempt, regardless of BMI. Our results are consistent with a study done by Heavens et al who explored the impact of TTI and external defibrillation outcome. They reported that TTI was not a major determinant of shock success as well as the event survival. 26 It has been shown that survival rates decline 7 to 10 percent for every minute that defibrillation is delayed, 27 and according to the 2010 AHA guidelines the time from sudden cardiac arrest to first shock delivery should be within 5-10 minutes for clinically beneficial outcome. 24, 28 We observed a consistent time interval between arrhythmia onset to shock delivery not longer than one minute, with a median of 47, 47, and 48 seconds respectively among the three different subgroups. Theoretically, obese patients could have more problems with appropriate fitting of the defibrillator garment leading to poor ECG quality and potential delay of crucial shock delivery but this does not appear to be the case.
Since the non-adhesive capacitive ECG electrodes of the WCD belt require proper skin contact in order to achieve a satisfactory ECG signal, the electrode belt must fit snug. Obese patients with excessive fat tissue around the chest may be more susceptible to motion artifacts due to rolling of tissue under the ECG electrodes. Our study observed a positive correlation between BMI groups and ECG noise from at least one of the two ECG leads. Compared to the normal and overweight groups, the obese group experienced a 66.7% increase in their noise rate (4.7% vs 2.9%); the morbidly obese group had a higher noise rate of 7.0%. However, majority of the noise sensed by the electrode belt was either not long enough to set off an alarm or resolved by patient's self-adjustment of the belt or using the response buttons. There was no difference in the occurrence of inappropriate shocks indicating that the WCD was safe used in all subgroups. Despite more ECG noise, we did not observe less daily WCD use in groups with higher BMI. The daily wear time was similar across the three groups. These findings are comparable to the recently published study by Kutyifa et al who reported a median daily wearing time of 22.5 hours per in 2000 WCD patients. 29 In our opinion, patient's wear time heavily depends upon 1) dedicated patient fitting and training by the manufacturer's training personnel and 2) thorough explanation by the caring physician about the need of uninterrupted WCD wearing. When looking at the WCD discontinuation reasons, majority of the patients received an ICD. Those who were lost to follow-up were few and the proportion was similar across the three groups.
Limitations
Our study represents a retrospective analysis of a large cohort of WCD patients with ventricular tachyarrhythmic events that received appropriate shock delivery leading to a very high successful conversion rate. Almost half of the eligible patients were missing a height value and thus were excluded from the final analysis. Due to the limitation of this registry, long-term survival and quality of life assessment were not recorded. Also, there were no control arms for each BMI subgroups without a VT/VF shock. We did not report different shock results potentially contributed by different underlying structural heart disease or significant co-morbidities. However, this was not the intention of our study, as we were interested in analyzing the effectiveness of appropriate shock delivery, wearing compliance and time of WCD use in patients with various BMI. The obese patient group was younger compared to the other two groups. Although age may not be a significant factor affecting TTI and first-shock success, it could impact event survival.
Conclusion
Our study shows that shock delivery of the WCD to convert life-threatening ventricular tachyarrhythmic events in high risk patients is similarly successful (93%-96%) in groups with normal, overweight or obese body weight despite significantly higher shock impedance in obese and morbid obese patients. We found no significant in post-SCA 24-hour survival. Overall WCD use was not significantly different among the three groups. Obese and morbid obese patients experienced more ECG noise but the occurrence of inappropriate shocks by noise was as low as the normal and overweight groups. Results suggest that there is no reason to exclude overweight and heavily overweight patients from prescribing the WCD.
Perspectives
This article provides previously unavailable data regarding the impact of obesity, evaluated by body mass index (BMI), on shock success and adherence among patients using a wearable cardioverter defibrillator (WCD). It shows that the first-shock success was 93%, 94%, and 94% in normal, overweight and obese group, respectively. In addition, the median daily wear time remained 21 hours among all BMI groups. This result is comparable to the recently published WEARIT II results. 29 It can help to alleviate such concern that putting a WCD on obese patients may lead to sub-optimal clinical outcome. It provides significant clinical relevance that WCD can be safely and effectively used in all patients regardless of BMI.
